Anika Therapeutics (NasdaqGS:ANIK) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Anika Therapeutics to reach your target.
Hmm, we can't give any reliable projection for Anika Therapeutics's growth rate. The company either has too few years of historical data for us to examine, or it's in the habit of losing money.
None of this means it's a bad stock. Maybe it's new and growing quickly, or maybe it's turning things around. We can't say anything sensible about it, so we won't say it's obviously undervalued right now. Proceed at your own risk!
| Advantages | Disadvantages | Neutral |
|---|---|---|
| None. |
|
|
| ANIK Price (Anika Therapeutics stock price per share) |
$13.23 | |
| PE Ratio versus Sector | 122% higher than other Unknown stocks | |
| PE Ratio versus Industry | 22% lower than other Unknown stocks | |
| Cash Yield | 21.43% | |
| Free Cash Flow Jitter | 100% |
In the six months to 2026-11-21, 1 insider bought in 2 trades, about $41 thousand, and no insider sold shares.
The six months before that had 2 buys and 0 sales.
Open-market buys and sells reported by Anika Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-04 | Fischetti Gary P | Buy | 1,000 | $20.32 |
| 2026-08-03 | Fischetti Gary P | Buy | 1,000 | $20.75 |
| 2026-05-01 | HENNEMAN JOHN B III | Buy | 5,000 | $14.66 |
| 2026-04-30 | Griffin Stephen D. (President and CEO) | Buy | 12,200 | $12.29 |
| 2022-05-11 | Colleran David (EVP, General Counsel, Corp Sec) | Buy | 1,500 | $21.37 |
| 2022-03-14 | Colleran David (EVP, General Counsel, Corp Sec) | Buy | 1,500 | $26.65 |
| 2022-03-11 | Levitz Michael L (EVP, CFO, Treasurer) | Buy | 4,000 | $24.62 |
| 2022-03-11 | Blanchard Cheryl R (President, CEO, Director) | Buy | 3,813 | $25.81 |
| 2022-03-11 | Blanchard Cheryl R (President, CEO, Director) | Buy | 4,287 | $25.36 |
| 2022-03-11 | Thompson Jeffery S | Buy | 2,000 | $24.66 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 323,508 shares shorted. With 11,297,607 shares available for purchase and an average trading volume over the past 10 trading days of 149,310, it would take at least 2.2 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
How to read this: what free cash flow is, why earnings matter.
Over the 12 fiscal years from 2009 to 2025 with positive net income, operating cash flow totaled $282 million against net income of $232 million, or 1.22 times. Net income was negative in 5 of the 17 years, and those years are left out of the ratio.
In 2025, net income was -$10.9 million and operating cash flow was $11.2 million, so no ratio is shown for that year.
In 2025, capital expenditures were $6.8 million, 61.0% of operating cash flow of $11.2 million, which leaves an estimated $4.4 million after capex. Across the 16 years with reported capex, it averaged 25.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2009 | 3.7 | 3.1 | 4 | 0.84 |
| 2010 | 4.3 | 7.9 | 2.8 | 1.82 |
| 2011 | 8.5 | 10.2 | 1.4 | 1.20 |
| 2012 | 11.8 | 10.5 | 1.5 | 0.90 |
| 2013 | 20.6 | 25.2 | 0.4 | 1.22 |
| 2014 | 38.3 | 40 | 1.6 | 1.04 |
| 2015 | 30.8 | 39.9 | 9.2 | 1.30 |
| 2016 | 32.5 | 24.4 | 14 | 0.75 |
| 2017 | 31.8 | 40.8 | 9 | 1.28 |
| 2018 | 18.7 | 34.9 | 4.7 | 1.87 |
| 2019 | 27.2 | 37 | 2.8 | 1.36 |
| 2020 | -24 | 13.1 | 1.6 | n/a |
| 2021 | 4.1 | 8.4 | 5.1 | 2.03 |
| 2022 | -14.9 | 4.4 | 7.5 | n/a |
| 2023 | -82.7 | -1.8 | 5.4 | n/a |
| 2024 | -56.4 | 5.4 | 7.7 | n/a |
| 2025 | -10.9 | 11.2 | 6.8 | n/a |
How to read this: why companies buy back shares, dividend yield explained.
Over the 7 fiscal years from 2014 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $112 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.
In 5 of the 7 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $101 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.
In 2025, cash spent repurchasing shares was $9.5 million, 203.3% of estimated free cash flow of $4.7 million. That was more than the estimated free cash flow of the year.
| Fiscal year | Estimated free cash flow (USD millions) | Dividends paid (USD millions) | Cash spent repurchasing shares (USD millions) | Total returned (USD millions) | Total as a percent of estimated free cash flow |
|---|---|---|---|---|---|
| 2014 | 38.4 | n/a | 6.3 | 6.3 | 16.5% |
| 2016 | 19.1 | n/a | 25 | 25 | 130.9% |
| 2018 | 27.2 | n/a | 30 | 30 | 110.2% |
| 2019 | 29.1 | n/a | 30 | 30 | 103.2% |
| 2023 | -6.3 | n/a | 5 | 5 | n/a |
| 2024 | -0.1 | n/a | 10.9 | 10.9 | n/a |
| 2025 | 4.7 | n/a | 9.5 | 9.5 | 203.3% |
Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.
How to read this: earnings and margins.
Revenue was $40.1 million in 2009 and $113 million in 2025, a compound annual growth rate of 6.7% over 16 years.
Revenue fell 5.9% from 2024 to 2025.
Our estimated free cash flow was $4.7 million in 2025, 4.1% of revenue. In 2009 the estimated margin was negative 2.2%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2009 | 40.1 | -0.9 | -2.2% |
| 2010 | 55.6 | 4.5 | 8.1% |
| 2011 | 64.8 | 7.5 | 11.5% |
| 2012 | 71.4 | 8.1 | 11.4% |
| 2013 | 75.1 | 23.1 | 30.8% |
| 2014 | 106 | 38.4 | 36.4% |
| 2015 | 93 | 37.1 | 39.9% |
| 2016 | 103 | 19.1 | 18.5% |
| 2017 | 113 | 34 | 30.0% |
| 2018 | 106 | 27.2 | 25.8% |
| 2019 | 115 | 29.1 | 25.4% |
| 2020 | 130 | 6.6 | 5.1% |
| 2021 | 148 | 3.8 | 2.5% |
| 2022 | 114 | 0.1 | 0.1% |
| 2023 | 121 | -6.3 | -5.2% |
| 2024 | 120 | -0.1 | -0.1% |
| 2025 | 113 | 4.7 | 4.1% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $57.5 million against total liabilities of $46.8 million, or 122.8% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 24.6% of total assets in 2025, compared with 33.9% in 2010, a decrease of 9.3 percentage points.
Stockholders equity was $143 million in 2025, compared with $85.2 million in 2010, a rise of 68.4%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 4.2% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2010 | 129 | 28.2 | 43.7 | 85.2 |
| 2011 | 133 | 35.8 | 38.1 | 94.8 |
| 2012 | 142 | 44.1 | 33.1 | 109 |
| 2013 | 156 | 63.3 | 20.4 | 136 |
| 2014 | 193 | 100 | 14.7 | 178 |
| 2015 | 236 | 111 | 24.9 | 211 |
| 2016 | 240 | 104 | 17.5 | 223 |
| 2017 | 283 | 133 | 19.1 | 263 |
| 2018 | 279 | 89 | 15.4 | 264 |
| 2019 | 331 | 157 | 42.3 | 288 |
| 2020 | 366 | 95.8 | 93.2 | 272 |
| 2021 | 348 | 94.4 | 60.5 | 287 |
| 2022 | 349 | 86.3 | 63.6 | 286 |
| 2023 | 271 | 68.7 | 58.4 | 212 |
| 2024 | 203 | 55.6 | 48.8 | 154 |
| 2025 | 190 | 57.5 | 46.8 | 143 |
We do not estimate a fair value for Anika Therapeutics while its free cash flow growth is not positive, so there is no value comparison here.
Only 14 of the 17 fiscal years under Anika Therapeutics's current filer show positive free cash flow.
Free cash flow is volatile from year to year, with a variability measure of 100%.
Before you act on any of this, read what a margin of safety means and check the company's own filings.
No dividend yield is recorded for Anika Therapeutics in our data.
Every fiscal year on this page is reported by one SEC filer, CIK 898437.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ANIK annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Anika Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ANIK: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
How Does Portfolio Churning Affect Your Returns?
Insider Buying as a Conviction Signal
What is Market Capitalization?
What is Cash Return on Invested Capital?